Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-01

Study Completion Date

2020-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We hypothesize that Dapagliflozin could improve the diuretic response in diabetic patients with acute decompensated heart failure owing to its diuretic effect in addition to improvement of blood glucose level without remarkable effect on kidney function or electrolytes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients

NCT03387683

Diabetes Mellitus Type 2

COMPLETED PHASE4

Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

NCT05335629

Myocardial Infarction Diabetes Mellitus, Type 2 Myocardial Remodeling, Ventricular

COMPLETED NA

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

NCT06982079

Chronic Kidney Disease Stage 5 CKD Stage 4

RECRUITING PHASE3

The DAPA-MEMRI Trial

NCT04591639

Heart Failure Diabetic Cardiomyopathies

RECRUITING NA

Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

NCT05050500

Myocardial Infarction Diabete Type 2 Glucose Intolerance

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will include 100 diabetic patients type 2 patients who will be admitted to care unit with decompensated heart failure.50 patient will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures ,the other group will receive insulin for control of blood sugar plus diuretics and anti-failure measures.

Inclusion Criteria:

Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no specified inclusion criterion with respect to heart failure etiology and/or ejection fraction.

Age more than 18 years Admission for acute decompensated heart failure The patient already on an oral loop diuretic for at least 1 month before admission, at a dose between 40 mg and 80 mg daily in the case of furosemide and an equivalent dose in the case of a different loop diuretic (20 mg of Torsemide will be considered to be equivalent to 40 mg of furosemide.

Exclusion Criteria:

1. Other etiologies of fluid overload different from heart failure.
2. Hyponatremia: Sodium level below 125mmol/l
3. Unstable patients: acute coronary syndrome, cardiogenic shock .
4. Patients requiring inotropic agents or renal dialysis.
5. Pregnancy or breastfeeding period.
6. sever hepatic disease
7. GFR (Glomerular Filtration Rate) is less than 45 mL/min/1.73 m² .
8. Patient with diabetic ketoacidosis or non ketotic hyperosmolar. Treatment arm.

The patients will receive:

Loop diuretics. Diuretics should be administered at doses sufficient to achieve optimal volume status and relieve congestion without inducing an excessively rapid reduction in intravascular volume.

furosemide will be given I.V either by continuous infusion or blouses Antifailure treatment: (Angiotensin converting enzyme inhibitors or Angiotensin II Receptor Blockers, Beta Blockers,Mineralocorticoid Receptor Antagonists, Ivabradine, or others will be individualized according to the patient condition.

Dapagliflozin:

will be given in a dose of 10mg once daily ( GFR is more than 45 mL/min/1.73 m²) .

In Mild or moderate hepatic disease: No dosage adjustment required In Severe hepatic disease: will not be used.

Insulin. Insulin therapy should be initiated if blood glucose levels is ≥180 mg/dL (10.0 mmol/L) after initiation of Dapagliflozin treatment. Once insulin therapy is started, a target glucose range of 140-180 mg/dL (7.8-10.0 mmol/L) is recommended The use of subcutaneous rapid- or short-acting insulin before meals or every 4-6 h will be given to correct hyperglycemia according to sliding scale chart.

Control arm.

The patients will be given Loop diuretics. Anti-failure treatment. Insulin.

All the patients will undergo:

1. Complete echo assessment.
2. ECG on admission and daily.
3. Monitoring:24 hours ECG ,Oxygen saturation and blood pressure monitoring. Complete blood count ,blood urea,serum creatinine,blood sugar,electrolytes ,liver function will be measured on admission
4. Blood sugar ,urea,creatinine,Na, K will be measured daily along the whole days of admission.

Follow up parameters

Diuresis :24-hour diuresis will be quantified every 24 hours (during hospitalization) from the 1st day until last day of admission.

diuretic response will be measured by weight loss and net fluid loss per mg . Changes in body weight measurements: the mean of weight lost every 24 hours and the total weight lost from baseline to the last day of hospitalization Renal function will be determined every 24 hours (during hospitalization) from the date of admission until the date of discharge.

Renal function is assessed with the serum creatinine level. Worsening renal function is defined as an increase in the serum creatinine level of more than 0.3 mg/dl at any time during hospitalization Electrolyte levels (sodium and potassium) will be determined every 24 hours (during hospitalization) from the date of admission until the date of discharge.

Electrolyte levels are assessed with the serum sodium and potassium levels. Patient-reported dyspnea : Patient-reported dyspnea is assessed every 24 hours (during hospitalization) from the date of admission until the date of discharge.

Patient-reported dyspnea will be assessed with the use five point Linker scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

The study will include 100 diabetic patients type 2 patients who will be admitted to care unit with decompensated heart failure.50 patient will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures ,the other group will receive insulin for control of blood sugar plus diuretics and anti-failure measures.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dapagliflozin group

50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.

Group Type ACTIVE_COMPARATOR

Dapagliflozin

Intervention Type DRUG

Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.

insulin

Intervention Type DRUG

insulin

Placebo group

50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.

Group Type PLACEBO_COMPARATOR

insulin

Intervention Type DRUG

insulin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dapagliflozin

Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.

Intervention Type DRUG

insulin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SGLT-2 inhibitors

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction.

Exclusion Criteria

1. Other etiologies of fluid overload different from heart failure.
2. Hyponatremia: Sodium level below 125mmol/l
3. Unstable patients: acute coronary syndrome, cardiogenic shock .
4. Patients requiring inotropic agents or renal dialysis.
5. Pregnancy or breastfeeding period.
6. sever hepatic disease
7. GFR is less than 45 mL/min/1.73 m² .
8. Patient with diabetic ketoacidosis or non ketotic hyperosmolar.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No